Therefore, a phase II clinical study of the multi-center, randomized, double-blind, placebo-controlled trial of VX-745 was conducted between December 29, 2017, and June 17, 2019, and it concluded that 24 weeks of VX-745 (40 mg, twice daily) treatment did not improve episodic memory in patients with mild AD compared to placebo, although the drug resulted in significant reductions of CSF total tau and p-tau 181 levels (ClinicalTrials.gov identifier: NCT03761849). Here, MAPT is linked to Alzheimer disease.